# 12-Month Prescription Decision Flowchart

**Evidence-based clinical decision guide | Updated February 2026**

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ“‹ COMPANION TOOL: Traffic Light Medication Checker  â”‚
â”‚ Use alongside this flowchart for medication details  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

---

## Quick Start Guide

**1ï¸âƒ£ Use this flowchart for the decision PROCESS**  
   Step-by-step: controlled drug? â†’ zone? â†’ patient factors? â†’ decision

**2ï¸âƒ£ Use Traffic Light Checker for MEDICATION details**  
   eGFR thresholds, monitoring requirements, specific guidance

**3ï¸âƒ£ Start at the top, follow arrows downward**  
   Most decisions take 2-5 minutes

**4ï¸âƒ£ Clinical judgment is paramount**  
   This is guidance, not a rigid protocol

ðŸ’¡ **TIP:** Keep both documents open side-by-side

---

```
                    PATIENT REQUESTS LONGER PRESCRIPTION
                                    â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  Is this a CONTROLLED DRUG?   â”‚
                    â”‚  (opioids, benzos, tramadol,  â”‚
                    â”‚   methylphenidate, etc.)      â”‚
                    â”‚  â†’ Check TRAFFIC LIGHT: ðŸ”´    â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“           â†“
                            YES          NO
                              â†“           â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”      â†“
                    â”‚ ðŸ”´ STOP      â”‚      â†“
                    â”‚ Max 1-3      â”‚      â†“
                    â”‚ months legal â”‚      â†“
                    â”‚ limit        â”‚      â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜      â†“
                                         â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  CHECK TRAFFIC LIGHT MEDICATION CHECKER    â”‚
                    â”‚                                            â”‚
                    â”‚  Is medication in ðŸ”´ RED ZONE?            â”‚
                    â”‚  (Requires regular blood test monitoring)  â”‚
                    â”‚                                            â”‚
                    â”‚  Examples:                                 â”‚
                    â”‚  â€¢ Warfarin, lithium, digoxin             â”‚
                    â”‚  â€¢ Methotrexate, azathioprine             â”‚
                    â”‚  â€¢ Antipsychotics (metabolic monitoring)  â”‚
                    â”‚  â€¢ Amiodarone, valproate, carbamazepine   â”‚
                    â”‚  â€¢ Insulin (regular dose adjustments)     â”‚
                    â”‚  â€¢ Oral steroids (chronic use)            â”‚
                    â”‚  â€¢ Immunosuppressants                      â”‚
                    â”‚                                            â”‚
                    â”‚  â†’ See Traffic Light Checker RED zone      â”‚
                    â”‚     for complete list                      â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                      YES (RED)          NO
                              â†“              â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â†“
                    â”‚ ðŸ”´ NOT SUITABLE  â”‚     â†“
                    â”‚ Max 3 months     â”‚     â†“
                    â”‚ Needs regular    â”‚     â†“
                    â”‚ monitoring       â”‚     â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â†“
                                             â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  Is medication in ðŸŸ¡ AMBER ZONE?          â”‚
                    â”‚  (Needs individual assessment)             â”‚
                    â”‚                                            â”‚
                    â”‚  â†’ OPEN TRAFFIC LIGHT CHECKER             â”‚
                    â”‚  â†’ Check AMBER SUMMARY TABLE              â”‚
                    â”‚                                            â”‚
                    â”‚  Common AMBER medications:                 â”‚
                    â”‚  ACEi/ARBs, Metformin, DOACs, NSAIDs,     â”‚
                    â”‚  Sulfonylureas, SGLT-2i, Gabapentin,      â”‚
                    â”‚  Spironolactone, Diuretics, TCAs          â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                      YES (AMBER)        NO (GREEN)
                              â†“              â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â†“
                    â”‚ ðŸŸ¡ USE AMBER SUMMARY TABLE:             â”‚  â†“
                    â”‚                                         â”‚  â†“
                    â”‚ 1. Find medication in summary table     â”‚  â†“
                    â”‚ 2. Check "Key Parameter" column        â”‚  â†“
                    â”‚    (eGFR, CrCl, age, etc.)             â”‚  â†“
                    â”‚ 3. Look up patient's value             â”‚  â†“
                    â”‚ 4. Read "12mo OK if:" column           â”‚  â†“
                    â”‚ 5. Check "MAX if:" column              â”‚  â†“
                    â”‚                                         â”‚  â†“
                    â”‚ Examples:                               â”‚  â†“
                    â”‚ â€¢ ACEi/ARB: eGFR â‰¥60 â†’ 12mo OK         â”‚  â†“
                    â”‚ â€¢ Metformin: eGFR >45 â†’ 12mo OK        â”‚  â†“
                    â”‚ â€¢ Sulfonylurea: Age <70 â†’ 12mo OK      â”‚  â†“
                    â”‚ â€¢ DOAC: See table (varies by drug)     â”‚  â†“
                    â”‚                                         â”‚  â†“
                    â”‚ âš ï¸ If borderline: 6 months safer       â”‚  â†“
                    â”‚                                         â”‚  â†“
                    â”‚ Need details? â†’ Scroll to detailed      â”‚  â†“
                    â”‚ section in Traffic Light Checker        â”‚  â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â†“
                              â†“              â†“
                      Criteria  Criteria     â†“
                       NOT met    met        â†“
                              â†“    â†“         â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â†“         â†“
                    â”‚ Use 3-6  â”‚   â†“         â†“
                    â”‚ months   â”‚   â†“         â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â†“         â†“
                                   â†“         â†“
                                   â†“         â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚ ðŸŸ¢ Medication suitable for 12 months       â”‚
                    â”‚ (if patient factors also suitable)         â”‚
                    â”‚                                            â”‚
                    â”‚ Examples from Traffic Light Checker:       â”‚
                    â”‚ â€¢ Statins, CCBs, beta blockers             â”‚
                    â”‚ â€¢ ICS/LABA, levothyroxine                  â”‚
                    â”‚ â€¢ SSRIs/SNRIs (with annual discussion)     â”‚
                    â”‚ â€¢ DPP-4 inhibitors, montelukast            â”‚
                    â”‚ â€¢ Dementia meds, levetiracetam             â”‚
                    â”‚ â€¢ Clopidogrel, aspirin (antiplatelet)      â”‚
                    â”‚                                            â”‚
                    â”‚ â†’ See Traffic Light Checker GREEN zone     â”‚
                    â”‚   for complete list + important caveats    â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                            â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  Is SPECIAL AUTHORITY required?    â”‚
                    â”‚  Will it remain valid for 12 months?â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                      Will expire         Valid
                           â†“                 â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â†“
                    â”‚ ðŸ”´ DECIDE:   â”‚         â†“
                    â”‚ â€¢ Shorter Rx â”‚         â†“
                    â”‚ â€¢ Plan SA    â”‚         â†“
                    â”‚   renewal    â”‚         â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â†“
                                             â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  PATIENT STABILITY ASSESSMENT      â”‚
                    â”‚  ðŸŸ¢ Guidance (not mandatory):      â”‚
                    â”‚                                    â”‚
                    â”‚  Is the CONDITION stable?          â”‚
                    â”‚  â€¢ Symptoms well-controlled        â”‚
                    â”‚  â€¢ No recent exacerbations         â”‚
                    â”‚  â€¢ No new diagnoses                â”‚
                    â”‚                                    â”‚
                    â”‚  Is the DOSE stable?               â”‚
                    â”‚  â€¢ No dose changes needed          â”‚
                    â”‚  â€¢ No medication switches          â”‚
                    â”‚                                    â”‚
                    â”‚  How long stable?                  â”‚
                    â”‚  â€¢ ðŸŸ¢ RNZCGP suggests: 6 months   â”‚
                    â”‚  â€¢ ðŸ”µ Your practice decides        â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                          UNSTABLE        STABLE
                              â†“              â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â†“
                    â”‚ ðŸŸ¢ Consider  â”‚         â†“
                    â”‚ shorter      â”‚         â†“
                    â”‚ duration:    â”‚         â†“
                    â”‚ â€¢ 3 months   â”‚         â†“
                    â”‚ â€¢ 6 months   â”‚         â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â†“
                                             â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  PATIENT CHARACTERISTICS           â”‚
                    â”‚  ðŸŸ¢ Consider (not exclusions):     â”‚
                    â”‚                                    â”‚
                    â”‚  High-consideration groups:        â”‚
                    â”‚  â˜ Age 65+ (closer monitoring)     â”‚
                    â”‚  â˜ Children/adolescents            â”‚
                    â”‚  â˜ Pregnant/breastfeeding          â”‚
                    â”‚  â˜ Polypharmacy (5+ meds)          â”‚
                    â”‚  â˜ Cognitive impairment            â”‚
                    â”‚  â˜ Poor adherence history          â”‚
                    â”‚  â˜ Unstable housing/transport      â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                    Multiple factors     Few/no factors
                              â†“              â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â†“
                    â”‚ ðŸŸ¢ May be better â”‚     â†“
                    â”‚ served by:       â”‚     â†“
                    â”‚ â€¢ 6 months       â”‚     â†“
                    â”‚ â€¢ More frequent  â”‚     â†“
                    â”‚   touchpoints    â”‚     â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â†“
                                             â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  EQUITY CONSIDERATIONS             â”‚
                    â”‚  ðŸŸ¢ RNZCGP guidance:               â”‚
                    â”‚                                    â”‚
                    â”‚  Will 12 months IMPROVE access?    â”‚
                    â”‚  â˜ Reduces cost barriers           â”‚
                    â”‚  â˜ Reduces transport barriers      â”‚
                    â”‚  â˜ Reduces time off work           â”‚
                    â”‚                                    â”‚
                    â”‚  Or WORSEN outcomes?               â”‚
                    â”‚  â˜ Reduces monitoring touchpoints  â”‚
                    â”‚  â˜ May miss deterioration          â”‚
                    â”‚  â˜ Reduces cultural connection     â”‚
                    â”‚                                    â”‚
                    â”‚  For MÄori patients:               â”‚
                    â”‚  Consider barriers/access carefullyâ”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                     May worsen          May improve
                              â†“              â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â†“
                    â”‚ ðŸŸ¢ Consider  â”‚         â†“
                    â”‚ 6 months     â”‚         â†“
                    â”‚ with better  â”‚         â†“
                    â”‚ support      â”‚         â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â†“
                                             â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  PATIENT AGREEMENT                 â”‚
                    â”‚  ðŸŸ¢ Recommended:                   â”‚
                    â”‚                                    â”‚
                    â”‚  Will patient agree to:            â”‚
                    â”‚  â˜ Annual review (minimum)         â”‚
                    â”‚  â˜ Monitoring as needed            â”‚
                    â”‚  â˜ Collect from same pharmacy      â”‚
                    â”‚  â˜ Contact if condition changes    â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                              â†“              â†“
                           Uncertain        Agrees
                              â†“              â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â†“
                    â”‚ ðŸŸ¢ Start with    â”‚     â†“
                    â”‚ shorter trial:   â”‚     â†“
                    â”‚ â€¢ 3-6 months     â”‚     â†“
                    â”‚ â€¢ Reassess       â”‚     â†“
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â†“
                                             â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  CLINICAL JUDGMENT                 â”‚
                    â”‚  ðŸ”´ You have FULL DISCRETION       â”‚
                    â”‚                                    â”‚
                    â”‚  Choose duration you're            â”‚
                    â”‚  comfortable with:                 â”‚
                    â”‚  â˜ 3 months (current standard)     â”‚
                    â”‚  â˜ 6 months (RNZCGP recommended)   â”‚
                    â”‚  â˜ 9 months (some practices trial) â”‚
                    â”‚  â˜ 12 months (new option)          â”‚
                    â”‚                                    â”‚
                    â”‚  There is NO wrong answer if       â”‚
                    â”‚  clinically justified              â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                                    â†“
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚  âœ“ ISSUE PRESCRIPTION              â”‚
                    â”‚                                    â”‚
                    â”‚  DOCUMENT:                         â”‚
                    â”‚  â€¢ Duration chosen & rationale     â”‚
                    â”‚  â€¢ Monitoring plan                 â”‚
                    â”‚  â€¢ Next review date                â”‚
                    â”‚  â€¢ Patient agreement               â”‚
                    â”‚                                    â”‚
                    â”‚  ðŸŸ¡ If RNZCGP-accredited:         â”‚
                    â”‚  â€¢ Follow practice policy          â”‚
                    â”‚  â€¢ Ensure audit tracking           â”‚
                    â”‚  â€¢ Book annual review              â”‚
                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Legend

ðŸ”´ **LEGAL REQUIREMENT** - Must comply (law/regulation)  
ðŸŸ¡ **PROFESSIONAL STANDARD** - Required for RNZCGP accreditation  
ðŸŸ¢ **GUIDANCE** - Recommended best practice (discretionary)  
ðŸ”µ **PRACTICE DECISION** - Your practice determines

---


---

## Remember

1. **6 months is completely acceptable** - RNZCGP recommended this as safer
2. **You determine "stable"** - no mandatory 6-month timeframe in law
3. **Start conservative** - you can always extend later
4. **Document your reasoning** - whatever duration you choose
5. **Consider equity** - will this help or hinder this patient?

---

**This flowchart is a guide, not a protocol. Your clinical judgment is paramount.**

**Version:** 2.0 | **Date:** February 2026
